Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. NVDA
5. STZ
6. MSFT
7. SPY
8. SKYD
9. IBM
10. CRWV

Go back to Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 9c

Allogene Therapeutics Reports Second Quarter 2022 Financial Results

August 9, 2022 4:02 PM EDT

U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks Expected to be the Industrys First Allogeneic CAR T Phase 2 Pivotal TrialClearance to Cover ALPHA2 Protocol and Chemistry Manufacturing and Controls (CMC) for Use of ALLO-501A Manufactured from Cell Forge 1 (CF1)CF1 is Projected to Support the Manufacture of ~20,000 Doses of AlloCAR T Products Annually at Scale CF1 Earned a LEED® Interior Design and Construction Gold Designation from the U.S Green Building CouncilCompany Plans to Evaluate Potential Phase 2... More